|
Marketing Authorisations
|
|
|
An orally administered alternative
|
|
|
|
|
|
|
Increases platelet count in some patients, but no demonstrated efficacy with respect to bleeding
|
|
|
|
|
|
Longer survival, but with a high incidence of serious adverse effects and drug interactions
|
|
|
|
|
|
|
|
|
Reduction in blood phenylalanine levels, but no demonstrated clinical efficacy, plus anaphylactic reactions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|